Pages that link to "Q37471315"
Jump to navigation
Jump to search
The following pages link to High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination (Q37471315):
Displaying 50 items.
- Recent strategies targeting HIV glycans in vaccine design (Q26823603) (← links)
- Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity (Q27654848) (← links)
- Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India (Q28483205) (← links)
- Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes (Q28752503) (← links)
- Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant (Q33812812) (← links)
- An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120 (Q33820645) (← links)
- Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects (Q33888559) (← links)
- Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response (Q33907538) (← links)
- Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds (Q33964006) (← links)
- Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody (Q33990484) (← links)
- The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. (Q34017550) (← links)
- Identifying and characterizing recently transmitted viruses (Q34038460) (← links)
- Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine (Q34157802) (← links)
- Folding domains within the ricin toxin A subunit as targets of protective antibodies (Q34196491) (← links)
- Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection (Q34203163) (← links)
- Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies (Q34392963) (← links)
- Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection (Q34402934) (← links)
- Specificity of the autologous neutralizing antibody response (Q34415389) (← links)
- Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity (Q34499013) (← links)
- Induction of immunity to human immunodeficiency virus type-1 by vaccination (Q34540645) (← links)
- Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic (Q35077704) (← links)
- HIV-1-specific antibody responses during acute and chronic HIV-1 infection (Q35096836) (← links)
- Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design (Q35196671) (← links)
- Binding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children (Q35604169) (← links)
- Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization (Q35691113) (← links)
- Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape (Q36000736) (← links)
- Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet (Q36057328) (← links)
- Discrete partitioning of HIV-1 Env forms revealed by viral capture. (Q36088254) (← links)
- Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs (Q36267348) (← links)
- Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study (Q36334371) (← links)
- Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors (Q36384117) (← links)
- Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide (Q36715717) (← links)
- Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock (Q36827377) (← links)
- Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds (Q36878885) (← links)
- Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection (Q37273158) (← links)
- HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. (Q37360774) (← links)
- Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection (Q37460580) (← links)
- HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study (Q37484124) (← links)
- Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking (Q37554149) (← links)
- Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. (Q38046828) (← links)
- Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). (Q38206519) (← links)
- Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. (Q38725480) (← links)
- Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. (Q38968180) (← links)
- The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity (Q39013830) (← links)
- Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection (Q39451862) (← links)
- Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5. (Q40187598) (← links)
- A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles (Q40220988) (← links)
- Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization (Q40415206) (← links)
- Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies (Q41573062) (← links)
- The Neutralizing Antibody Response To the HIV-1 Env Protein. (Q46180922) (← links)